Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

You can read more here about inhalers for COPD treatment. Only nebulizers can deliver certain COPD drugs, including metaproterenol and acetylcysteine. Many factors go into deciding what type of ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.